<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38304439</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-2360</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in pediatrics</Title><ISOAbbreviation>Front Pediatr</ISOAbbreviation></Journal><ArticleTitle>Case Report: Successful avoidance of etoposide for primary hemophagocytic lymphohistiocytosis-induced multiple organ dysfunction syndrome using emapalumab.</ArticleTitle><Pagination><StartPage>1340360</StartPage><MedlinePgn>1340360</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1340360</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fped.2023.1340360</ELocationID><Abstract><AbstractText>We describe the case of an infant who presented with simple rhinovirus/enterovirus bronchiolitis whose condition worsened with rapid progression to multiple organ dysfunction syndrome (MODS). The patient was presumed to have either primary or secondary hemophagocytic lymphohistiocytosis (HLH), and treatment was initiated using dexamethasone, anakinra, and intravenous immunoglobulin to modulate the immune system. Due to the organ dysfunction, the use of etoposide was avoided and instead, emapalumab, an interferon gamma antagonist, was administered at a dose of 6 mg/kg. The patient's organ failure improved, and the levels of inflammatory markers decreased. The flow cytometry analysis revealed that cytotoxic cells lacked perforin expression, and subsequent genetic analysis confirmed homozygous pathogenic mutations in the perforin gene. This case highlights the potential avoidance of etoposide in cases of primary HLH, the possible benefit of an elevated initial dose of emapalumab, and the contribution offered by a multi-specialty team approach to complex diagnosis.</AbstractText><CopyrightInformation>© 2024 Hahn, McKeone, Beal, Ericson and Halstead.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Pediatric Rheumatology, Department of Pediatrics, Penn State University College of Medicine, Hershey, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dysregulated Immune Response Team (DIRT), Department of Pediatrics, Penn State University College of Medicine, Hershey, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeone</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Dysregulated Immune Response Team (DIRT), Department of Pediatrics, Penn State University College of Medicine, Hershey, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Hematology and Oncology, Department of Pediatrics, Penn State University College of Medicine, Hershey, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beal</LastName><ForeName>James W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Penn State University College of Medicine, Hershey, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ericson</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Dysregulated Immune Response Team (DIRT), Department of Pediatrics, Penn State University College of Medicine, Hershey, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Infectious Disease, Department of Pediatrics, Penn State University College of Medicine, Hershey, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halstead</LastName><ForeName>E Scott</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Dysregulated Immune Response Team (DIRT), Department of Pediatrics, Penn State University College of Medicine, Hershey, PA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Penn State University College of Medicine, Hershey, PA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pediatr</MedlineTA><NlmUniqueID>101615492</NlmUniqueID><ISSNLinking>2296-2360</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLH</Keyword><Keyword MajorTopicYN="N">MODS</Keyword><Keyword MajorTopicYN="N">emapalumab</Keyword><Keyword MajorTopicYN="N">ferritin</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword></KeywordList><CoiStatement>EH serves as a member of SOBI pharmaceuticals’ speaker bureau whose goal is to educate healthcare providers regarding hemophagocytic lymphohistiocytosis (HLH) and the drug, emapalumab. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>4</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38304439</ArticleId><ArticleId IdType="pmc">PMC10830683</ArticleId><ArticleId IdType="doi">10.3389/fped.2023.1340360</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matics TJ, Sanchez-Pinto LN. Adaptation and validation of a pediatric sequential organ failure assessment score and evaluation of the sepsis-3 definitions in critically ill children. JAMA Pediatr. (2017) 171(10):e172352. 10.1001/jamapediatrics.2017.2352</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2017.2352</ArticleId><ArticleId IdType="pmc">PMC6583375</ArticleId><ArticleId IdType="pubmed">28783810</ArticleId></ArticleIdList></Reference><Reference><Citation>Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. (2007) 48(2):124–31. 10.1002/pbc.21039</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.21039</ArticleId><ArticleId IdType="pubmed">16937360</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead ES, Rajasekaran S, Fitzgerald JC, Weiss SL. Hyperferritinemic sepsis: an opportunity for earlier diagnosis and intervention? Front Pediatr. (2016) 4:77. 10.3389/fped.2016.00077</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2016.00077</ArticleId><ArticleId IdType="pmc">PMC4969285</ArticleId><ArticleId IdType="pubmed">27532033</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeone DJ, DeMartini TKM, Kavanagh RP, Halstead ES. Case report: rapid recognition and immune modulation of secondary HLH due to disseminated HSV infection. Front Pediatr. (2021) 9:681055. 10.3389/fped.2021.681055</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2021.681055</ArticleId><ArticleId IdType="pmc">PMC8282902</ArticleId><ArticleId IdType="pubmed">34277520</ArticleId></ArticleIdList></Reference><Reference><Citation>Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. (2007) 166(2):95–109. 10.1007/s00431-006-0258-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-006-0258-1</ArticleId><ArticleId IdType="pubmed">17151879</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. (2009) 10(3):387–92. 10.1097/PCC.0b013e3181a1ae08</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181a1ae08</ArticleId><ArticleId IdType="pubmed">19325510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Scull BP, Goldberg BR, Abhyankar HA, Eckstein OE, Zinn DJ, et al. IFN-gamma signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Adv. (2021) 5(17):3457–67. 10.1182/bloodadvances.2021004287</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021004287</ArticleId><ArticleId IdType="pmc">PMC8525230</ArticleId><ArticleId IdType="pubmed">34461635</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacqmin P, Laveille C, Snoeck E, Jordan MB, Locatelli F, Ballabio M, et al. Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: a pharmacometric model-based approach. Br J Clin Pharmacol. (2022) 88(5):2128–39. 10.1111/bcp.15133</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15133</ArticleId><ArticleId IdType="pmc">PMC9305196</ArticleId><ArticleId IdType="pubmed">34935183</ArticleId></ArticleIdList></Reference><Reference><Citation>Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. (2020) 382(19):1811–22. 10.1056/NEJMoa1911326</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1911326</ArticleId><ArticleId IdType="pubmed">32374962</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. (2008) 50(6):1227–35. 10.1002/pbc.21423</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.21423</ArticleId><ArticleId IdType="pubmed">18085676</ArticleId></ArticleIdList></Reference><Reference><Citation>Krei JM, Moller HJ, Larsen JB. The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome—a systematic review. Clin Exp Immunol. (2021) 203(2):174–82. 10.1111/cei.13543</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13543</ArticleId><ArticleId IdType="pmc">PMC7806447</ArticleId><ArticleId IdType="pubmed">33128796</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>